Literature DB >> 2113074

Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.

M Salfinger1, A J Crowle, L B Reller.   

Abstract

Pyrazinamide (PZA) has become an essential component of current 6-month regimens for therapy of tuberculosis. Susceptible strains of tubercle bacilli convert PZA to pyrazinoic acid (POA) through pyrazinamidase (PZase), which resistant strains and Mycobacterium bovis bacille Calmette-Guérin lack. PZA susceptibility results obtained in cultured human macrophages were compared with those in the broth BACTEC system with 7H12 medium at pH 6.0 for strains known to be PZase-positive or -negative. Although added POA was unable to inhibit tubercle bacilli in cultured macrophages, it was able to inhibit them at very high concentrations in the BACTEC broth. Intracellularly formed POA would not be able to escape from the macrophage, and therefore would accumulate sufficiently to lower pH to toxic levels for tubercle bacilli. The results suggest that the cultured macrophages contribute actively or passively to the effectiveness of PZA, such as through the proposed mechanism of low pH generated by PZase in the phagolysosomes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113074     DOI: 10.1093/infdis/162.1.201

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.

Authors:  N Mor; A Esfandiari
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.

Authors:  Helena I Boshoff; Valerie Mizrahi; Clifton E Barry
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

4.  Intrapulmonary concentrations of pyrazinamide.

Authors:  J E Conte; J A Golden; S Duncan; E McKenna; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis.

Authors:  Takemasa Takii; Sonomi Hamasaki; Kazue Hirano; Chiyoji Abe; Kikuo Onozaki
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.

Authors:  Oren Zimhony; Catherine Vilchèze; Masayoshi Arai; John T Welch; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

7.  Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis.

Authors:  Takemasa Takii; Yoshifumi Yamamoto; Taku Chiba; Chiyoji Abe; John T Belisle; Patrick J Brennan; Kikuo Onozaki
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  In vitro antimycobacterial activities of pyrazinamide analogs.

Authors:  S Yamamoto; I Toida; N Watanabe; T Ura
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

9.  Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic.

Authors:  A J Crowle; R Dahl; E Ross; M H May
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

Review 10.  Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Gilbert Deray
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.